fda semaglutide mash Approves Wegovy® as First Treatment FDA Grants Accelerated Approval of

may have important implications on the accessibility and adherence of these drugs in the future, [because] currently all agents approved for weight loss are injections. The results showed frequent adverse events during the trials, ranging from 80% to 97% for GLP-1 receptor agonists and coagonists and 63% to 100% for placebo

Seek emergency medical care (call 911) if experiencing: Seizure activity Convulsions, loss of consciousness, uncontrolled shaking, or post-event confusion Severe hypoglycemia symptoms Extreme confusion, loss of consciousness, inability to swallow, or seizure in a patient with diabetes Signs of severe dehydration Inability to urinate, extreme dizziness, rapid heartbeat, or altered mental status Severe abdominal pain Particularly if radiating to the back, which may indicate pancreatitis Allergic reactions Difficulty breathing, throat swelling, or widespread rash Contact your healthcare provider within 24 hours for: Persistent vomiting preventing medication or fluid intake for more than 24 hours, signs of dehydration (decreased urination, persistent dizziness), unexplained neurological symptoms (numbness, tingling, vision changes, severe headache), symptoms of hypoglycemia occurring frequently despite medication adjustments, or severe gastrointestinal symptoms not improving with standard management

We also offer BCAAs which are branched-chain amino acids that help with muscle recovery and endurance

The Florida Department of Health did not respond to requests for comment on this story